Details for Patent: 8,188,271

Title:	Polycyclic carbamoylpyridone derivative having HIV integrase inhibitory activity
Abstract:	Is to provide a novel compound having an anti-viral activity, particularly a HIV integrase inhibitory activity, and a pharmaceutical composition, particularly an anti-HIV agent. ##STR00001## (wherein R.sup.1 is hydrogen or lower alkyl; X is lower alkylene etc.; R.sup.2 is optionally substituted aryl; R.sup.3 is hydrogen, halogen, hydroxy, optionally substituted lower alkyl etc.; R.sup.4 is hydrogen, optionally substituted lower alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkyl lower alkyl, optionally substituted aryl, optionally substituted aryl lower alkyl, optionally substituted heterocyclic group, optionally substituted heterocyclic lower alkyl etc.; A broken line indicates the presence or absence of a bond; B.sup.1 and B.sup.2 are such that any one of them is CR.sup.20R.sup.21, and the other is NR.sup.22 and, in this case, there is no broken line. When B.sup.2 is NR.sup.22, R.sup.4 and R.sup.22 may be connected together to form an optionally substituted heterocycle; When B.sup.2 is CHR.sup.21, R.sup.4 and R.sup.21 may be connected together to form an optionally substituted heterocycle. Alternatively, B.sup.1 and B.sup.2 are independently C, CR.sup.23 or N and, in this case, B.sup.1 and B.sup.2 may be taken together to form a heterocycle. R.sup.20, R.sup.21, R.sup.22 and R.sup.23 are independently hydrogen, optionally substituted lower alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkyl lower alkyl etc.)
Inventor(s):	Yoshida; Hiroshi (Osaka, JP), Kawasuji; Takashi (Osaka, JP), Taishi; Teruhiko (Koka, JP), Taoda; Yoshiyuki (Osaka, JP)
Assignee:	Shionogi & Co., Ltd. (Osaka, JP)
Filing Date:	Oct 26, 2006
Application Number:	12/084,128
Claims:	1. A compound of the formula: ##STR00286## (wherein, R.sup.1 is hydrogen or lower alkyl; X is a single bond, a heteroatom group selected from the group consisting of O, S, SO, SO.sub.2 and NH, or lower alkylene or lower alkenylene each may be intervened by the heteroatom group; R.sup.2 is optionally substituted aryl; R.sup.3 is hydrogen, halogen, hydroxy, optionally substituted lower alkyl, optionally substituted cycloalkyl, optionally substituted lower alkenyl, optionally substituted lower alkoxy, optionally substituted lower alkenyloxy, optionally substituted aryl, optionally substituted aryloxy, optionally substituted heterocyclic group, optionally substituted heterocycleoxy or optionally substituted amino, R.sup.4 is hydrogen, optionally substituted lower alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkyl lower alkyl, optionally substituted lower alkenyl, optionally substituted lower alkoxy, optionally substituted aryl, optionally substituted aryl lower alkyl, optionally substituted aryloxy, optionally substituted heterocycle, optionally substituted heterocycle lower alkyl, optionally substituted heterocycleoxy, hydroxy, optionally substituted amino, optionally substituted phosphoric acid residue, aryl substituted with optionally substituted phosphoric acid residue, aralkyl substituted with optionally substituted phosphoric acid residue, hydroxy substituted with optionally substituted phosphoric acid residue, amino substituted with optionally substituted phosphoric acid residue or lower alkyl substituted with optionally substituted phosphoric acid residue (the lower alkyl may be intervened by a heteroatom group selected from the group consisting of O, S, SO, SO.sub.2, NR.sup.a (R.sup.a is hydrogen or lower alkyl), --N.dbd. and .dbd.N--)); the broken line represents the presence or absence of a bond; one of B.sup.1 and B.sup.2 is CR.sup.20R.sup.21 and another is NR.sup.22, where the broken line represents the absence of a bond; or one of B.sup.1 and B.sup.2 is CR.sup.23 and another is N, where the broken line represents the presence of a bond; R.sup.20, R.sup.21, R.sup.22 and R.sup.23 are each independently, hydrogen, optionally substituted lower alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkyl lower alkyl, optionally substituted lower alkenyl, optionally substituted lower alkoxy, optionally substituted lower alkenyloxy, optionally substituted aryl, optionally substituted aryl lower alkyl, optionally substituted aryloxy, optionally substituted heterocycle, optionally substituted heterocycle lower alkyl, optionally substituted heterocycleoxy, optionally substituted phosphoric acid residue, aryl substituted with optionally substituted phosphoric acid residue, aralkyl substituted with optionally substituted phosphoric acid residue, hydroxy substituted with optionally substituted phosphoric acid residue, amino substituted with optionally substituted phosphoric acid residue or lower alkyl substituted with optionally substituted phosphoric acid residue (the lower alkyl may be intervened by a heteroatom group selected from the group consisting of O, S, SO, SO.sub.2, NR.sup.5 (R.sup.5 is independently selected from the same substitution group as R.sup.4), --N.dbd. and .dbd.N--), hydroxy, optionally substituted amino, optionally substituted lower alkylcarbonyl, optionally substituted cycloalkylcarbonyl, optionally substituted cycloalkyl lower alkyl carbonyl, optionally substituted lower alkoxycarbonyl, optionally substituted aryl carbonyl, optionally substituted aryl lower alkylcarbonyl, optionally substituted aryl oxycarbonyl, optionally substituted heterocyclecarbonyl, optionally substituted heterocycle lower alkylcarbonyl, optionally substituted heterocycleoxycarbonyl, optionally substituted aminocarbonyl, substituted thiourea or substituted sulfonyl), or a pharmaceutically acceptable salt thereof. 2. A compound of the formula: ##STR00287## (wherein, R.sup.1 is hydrogen or lower alkyl; X is a single bond, a heteroatom group selected from the group consisting of O, S, SO, SO.sub.2 and NH, or lower alkylene or lower alkenylene each may be intervened by the heteroatom group; R.sup.2 is optionally substituted aryl; R.sup.3 is hydrogen, halogen, hydroxy, optionally substituted lower alkyl, optionally substituted cycloalkyl, optionally substituted lower alkenyl, optionally substituted lower alkoxy, optionally substituted lower alkenyloxy, optionally substituted aryl, optionally substituted aryloxy, optionally substituted heterocyclic group, optionally substituted heterocycleoxy or optionally substituted amino; R.sup.4 is hydrogen, optionally substituted lower alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkyl lower alkyl, optionally substituted lower alkenyl, optionally substituted lower alkoxy, optionally substituted aryl, optionally substituted aryl lower alkyl, optionally substituted aryloxy, optionally substituted heterocycle, optionally substituted heterocycle lower alkyl, optionally substituted heterocycleoxy, hydroxy, optionally substituted amino, optionally substituted phosphoric acid residue, aryl substituted with optionally substituted phosphoric acid residue, aralkyl substituted with optionally substituted phosphoric acid residue, hydroxy substituted with optionally substituted phosphoric acid residue, amino substituted with optionally substituted phosphoric acid residue or lower alkyl substituted with optionally substituted phosphoric acid residue (the lower alkyl may be intervened by a heteroatom group selected from the group consisting of O, S, SO, SO.sub.2, NR.sup.a (R.sup.a is hydrogen or lower alkyl), --N.dbd. and .dbd.N--)); one of B.sup.1 and B.sup.2 is CR.sup.20R.sup.21 and another is NR.sup.22; R.sup.20, R.sup.21 and R.sup.22 are each independently, hydrogen, optionally substituted lower alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkyl lower alkyl, optionally substituted lower alkenyl, optionally substituted lower alkoxy, optionally substituted lower alkenyloxy, optionally substituted aryl, optionally substituted aryl lower alkyl, optionally substituted aryloxy, optionally substituted heterocycle, optionally substituted heterocycle lower alkyl, optionally substituted heterocycleoxy, hydroxy, optionally substituted amino, optionally substituted lower alkylcarbonyl, optionally substituted cycloalkylcarbonyl, optionally substituted cycloalkyl lower alkyl carbonyl, optionally substituted lower alkoxycarbonyl, optionally substituted aryl carbonyl, optionally substituted aryl lower alkylcarbonyl, optionally substituted aryl oxycarbonyl, optionally substituted heterocyclecarbonyl, optionally substituted heterocycle lower alkylcarbonyl, optionally substituted heterocycleoxycarbonyl, optionally substituted aminocarbonyl, substituted thiourea or substituted sulfonyl), according to claim 1, or a pharmaceutically acceptable salt thereof. 3. The compound according to claim 2, or pharmaceutically acceptable salt thereof, wherein B.sup.1 is CR.sup.20R.sup.21 and B.sup.2 is NR.sup.22 (R.sup.20, R.sup.21 and R.sup.22 are the same as defined in claim 2). 4. The compound according to claim 2, or pharmaceutically acceptable salt thereof, wherein B.sup.1 is NR.sup.22 and B.sup.2 is CR.sup.20R.sup.21 (R.sup.20, R.sup.21 and R.sup.22 are the same as defined in claim 2). 5. The compound according to claim 2, or pharmaceutically acceptable salt thereof, wherein B.sup.1 is NR.sup.22 (R.sup.22 is the same as defined in claim 2) and B.sup.2 is CH.sub.2. 6. The compound according to claim 2, or pharmaceutically acceptable salt thereof, wherein B.sup.1 is NR.sup.22 (R.sup.22 is hydrogen, optionally substituted lower alkyl, lower alkenyl, optionally substituted cycloalkyl, optionally substituted cycloalkyl lower alkyl, optionally substituted aryl, optionally substituted aryl lower alkyl, optionally substituted heterocycle, optionally substituted heterocycle lower alkyl, optionally substituted lower alkylcarbonyl, optionally substituted aryl carbonyl, substituted thiourea or substituted sulfonyl), and B.sup.2 is CH.sub.2. 7. The compound according to claim 2, or pharmaceutically acceptable salt thereof, wherein R.sup.4 is optionally substituted lower alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkyl lower alkyl, optionally substituted aryl, optionally substituted aryl lower alkyl, optionally substituted heterocycle, or optionally substituted heterocycle lower alkyl. 8. The compound according to claim 2, or pharmaceutically acceptable salt thereof, wherein B.sup.1 is NR.sup.22 (R.sup.22 is hydrogen, optionally substituted lower alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkyl lower alkyl, optionally substituted aryl, optionally substituted aryl lower alkyl, optionally substituted heterocycle, optionally substituted heterocycle lower alkyl, optionally substituted lower alkylcarbonyl, optionally substituted aryl carbonyl, substituted thiourea or substituted sulfonyl), B.sup.2 is CH.sub.2 and R.sup.4 is optionally substituted lower alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkyl lower alkyl, optionally substituted aryl, optionally substituted aryl lower alkyl, optionally substituted heterocycle, or optionally substituted heterocycle lower alkyl. 9. The compound according to claim 2, or pharmaceutically acceptable salt thereof, wherein B.sup.1 is NR.sup.22 (R.sup.22 is hydrogen, optionally substituted lower alkyl (substituent: amino, lower alkylamino, lower alkoxy, aryloxy, cyano, halogen, optionally substituted carbamoyl, acylamino lower alkynyl, hydroxy), cycloalkyl, cycloalkyl lower alkyl, optionally substituted phenyl, optionally substituted benzyl, optionally substituted 5- to 6-membered aromatic heterocycle, optionally substituted 5- to 6-membered heterocycle lower alkyl, optionally substituted lower alkylcarbonyl (substituent: lower alkoxy), optionally substituted benzoyl (substituent: lower alkoxy), substituted sulfonyl (substituent: lower alkyl, aryl, heterocycle)), B.sup.2 is CH.sub.2 and R.sup.4 is optionally substituted lower alkyl (substituent: amino, lower alkylamino, lower alkoxy, aryloxy), cycloalkyl, cycloalkyl lower alkyl, optionally substituted phenyl, optionally substituted benzyl, optionally substituted 5- to 6-membered aromatic heterocycle, or optionally substituted 5- to 6-membered heterocycle lower alkyl). 10. The compound according to claim 1, or pharmaceutically acceptable salt thereof, wherein R.sup.1 is hydrogen or lower alkyl. 11. The compound according to claim 1, or pharmaceutically acceptable salt thereof, wherein X is lower alkylene; R.sup.2 is phenyl or phenyl substituted with at least halogen. 12. The compound according to claim 1, or pharmaceutically acceptable salt thereof, wherein R.sup.3 is hydrogen. 13. The compound according to claim 1, or pharmaceutically acceptable salt thereof, wherein R.sup.1 is hydrogen or lower alkyl; X is lower alkylene; R.sup.2 is phenyl or phenyl substituted with 1 to 2 halogen; and R.sup.3 is hydrogen. 14. A pharmaceutical composition comprising a compound according to claim 1, or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent.